Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises [Yahoo! Finance]
Blueprint Medicines Corporation (BPMC)
Last blueprint medicines corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
blueprintmedicines.com
Company Research
Source: Yahoo! Finance
On a reported basis, the company recorded earnings of $1.40 per share in the first quarter upon recognizing a one-time income of debt extinguishment gain, amounting to $174.9 million. Quarterly revenues of $96.1 million also surpassed the Zacks Consensus Estimate of $82.6 million. Total revenues jumped 51.9% year over year. The stock rose 12.8% in the last trading session on May 2, and continued to gain another 2.8% in the after-market hours, as the investors cheered the earnings and revenue beat on the back of the strong performance of its marketed product. Year to date, Blueprint has gained 16% against the industry's decline of 8.8%. Image Source: Zacks Investment Research Quarter in Detail Blueprint's total revenues comprise net product revenues from Ayvakit/Ayvakyt and collaboration revenues. Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA proteins, is approved for treating PDGFRA Exon 18 mutant gastrointestinal stromal tumors and advanced and indolent systemic m
Show less
Read more
Impact Snapshot
Event Time:
BPMC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPMC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPMC alerts
High impacting Blueprint Medicines Corporation news events
Weekly update
A roundup of the hottest topics
BPMC
News
- Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at Stephens. They set an "overweight" rating and a $140.00 price target on the stock.MarketBeat
- Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update [Yahoo! Finance]Yahoo! Finance
- Blueprint Medicines Co. (NASDAQ: BPMC) was upgraded by analysts at Leerink Partnrs from an "underperform" rating to a "market perform" rating.MarketBeat
- Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $121.00 to $168.00. They now have a "buy" rating on the stock.MarketBeat
BPMC
Earnings
- 5/2/24 - Beat
BPMC
Sec Filings
- 5/17/24 - Form 4
- 5/17/24 - Form 4
- 5/15/24 - Form 144
- BPMC's page on the SEC website